skip to Main Content
placeholder

COVID-19 CD8+ Analysis

Current clinical trials are underway to evaluate the most appropriate medical interventions that will prevent and/or treat the severe hallmarks of COVID-19, namely multi-organ failure of the lungs, heart, kidneys and other organs, while work continues toward the development of effective vaccines. Imaging Endpoints is partnering to develop CD8+ and CD4+ cell-specific PET tracers that have shown promising results in preventative and treatment-related pre-clinical studies, as well as in a first in human, phase I trial. Learn more at https://imagingendpoints.com/covid-19/covid-19-cd8-analysis/.

Back To Top